The RGTA® technology fosters tissue healing 
and regeneration by Matrix Therapy

Cacipliq 20®
Cacipliq 20®

Cacipliq 20®

Cacipliq 20® is the first therapeutic product based on the innovative RGTA® technology.

Cacipliq 20® is dedicated for wound healing (CE marked medical devices).

Cacipliq 20®
Cacipliq 20®
Description

Cacipliq 20® belongs to the family of ReGeneraTing Agents (RGTA®), which are engineered biodegradable sugar based polymers.

Cacipliq 20® protects extracellular matrix proteins from the inside, hence restoring the matrix architecture. It preserves the natural cellular micro-environment of the wound and the endogenous factors needed for tissue regeneration.

Cacipliq 20® is a sterile wound healing solution.

Cacipliq 20® is a class III CE marked Medical Device.

Applied twice a week (every 3 to 4 days), Cacipliq 20® is a unique product which provides an easy-to-use, effective tissue regenerating solution for rapid wound healing.

Warnings and contraindications exist, please read the instructions. 

RGTA® in Matrix Therapy

Cacipliq 20®
Cacipliq 20®
Cacipliq 20®
Cacipliq 20®

Organes Tissus Regeneration Reparation Remplacement

© 2022 – OTR3 – All rights reserved

ADDRESS

4, rue Française
75001 Paris, France

© 2022 – OTR3 – All rights reserved

19/03/CCP/PM/001 – version 1 / Mars 2019